Masimo Co. (NASDAQ:MASI – Get Free Report) Director Craig B. Reynolds sold 2,053 shares of the stock in a transaction on Friday, March 14th. The stock was sold at an average price of $166.13, for a total value of $341,064.89. Following the completion of the transaction, the director now directly owns 16,581 shares of the company’s stock, valued at approximately $2,754,601.53. The trade was a 11.02 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Masimo Price Performance
Masimo stock opened at $168.21 on Friday. The company has a market capitalization of $9.07 billion, a price-to-earnings ratio of 116.01 and a beta of 1.03. Masimo Co. has a 12 month low of $101.61 and a 12 month high of $194.88. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. The stock’s 50 day moving average is $174.84 and its 200-day moving average is $157.36.
Masimo (NASDAQ:MASI – Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.38. The company had revenue of $600.70 million for the quarter, compared to the consensus estimate of $593.35 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. Equities research analysts expect that Masimo Co. will post 4.1 EPS for the current year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
MASI has been the subject of a number of recent analyst reports. Stifel Nicolaus reiterated a “buy” rating and issued a $190.00 price target (up previously from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research note on Wednesday, February 26th. Wells Fargo & Company raised their price target on Masimo from $193.00 to $205.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Piper Sandler increased their price objective on Masimo from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Finally, Raymond James raised their target price on Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a report on Friday, December 27th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $194.80.
Check Out Our Latest Report on MASI
Masimo Company Profile
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.
Featured Articles
- Five stocks we like better than Masimo
- What Investors Need to Know to Beat the Market
- MarketBeat Week in Review – 03/10 – 03/14
- What Are the U.K. Market Holidays? How to Invest and Trade
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- About the Markup Calculator
- How Super Micro Computer Stock Is Defying the Market Sell-Off
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.